CPHI Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
948.3K
-3.6%
983.5K
-19.8%
1.2M
+62.1%
756.2K
-26.3%
1.0M
Cost of Revenue
864.8K
+23.9%
698.0K
-35.1%
1.1M
+31.8%
815.9K
-26.7%
1.1M
Gross Profit
83.6K
-70.7%
285.5K
+89.3%
150.8K
+352.7%
-59654
+31.4%
-87010
Operating Expenses
1.5M
+8.0%
1.4M
+3.8%
1.4M
+137.6%
568.5K
+37.2%
414.4K
R&D
19.1K
-77.2%
83.8K
-55.9%
190.0K
+371.3%
40.3K
+131.1%
-129738
SG&A
1.5M
+12.8%
1.3M
+11.3%
1.2M
+136.2%
502.9K
-7.2%
542.1K
Operating Income
-1431845
-28.2%
-1117264
+6.9%
-1200195
-91.1%
-628145
-25.3%
-501430
EBITDA
-329990
-141.4%
-136694
+80.5%
-702770
-158.3%
-272111
-50.7%
-180567
Net Income
-1458123
-27.6%
-1143148
+6.5%
-1222135
-87.6%
-651482
-23.3%
-528367
EPS (Basic)
$-0.04
+0.0%
$-0.04
+77.8%
$-0.18
-5.9%
$-0.17
-6.3%
$-0.16
EPS (Diluted)
$-0.04
+0.0%
$-0.04
+77.8%
$-0.18
-5.9%
$-0.17
-6.3%
$-0.16
Shares (Diluted)
40.5M
+58.3%
25.6M
+276.3%
6.8M
+75.6%
3.9M
+20.1%
3.2M
China Pharma (CPHI) โ€” Financials